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We conducted a population-based study of 627 patients with biliary tract cancers (368 of gallbladder, 191 bile duct, and 68 ampulla
of Vater), 1037 with biliary stones, and 959 healthy controls randomly selected from the Shanghai population, all personally
interviewed. Gallstone status was based on information from self-reports, imaging procedures, surgical notes, and medical records.
Among controls, a transabdominal ultrasound was performed to detect asymptomatic gallstones. Gallstones removed from cancer
cases and gallstone patients were classified by size, weight, colour, pattern, and content of cholesterol, bilirubin, and bile acids. Of the
cancer patients, 69% had gallstones compared with 23% of the population controls. Compared with subjects without gallstones, odds
ratios associated with gallstones were 23.8 (95% confidence interval (CI), 17.0–33.4), 8.0 (95% CI 5.6–11.4), and 4.2 (95% CI 2.5–
7.0) for cancers of the gallbladder, extrahepatic bile ducts, and ampulla of Vater, respectively, persisting when restricted to those with
gallstones at least 10 years prior to cancer. Biliary cancer risks were higher among subjects with both gallstones and self-reported
cholecystitis, particularly for gallbladder cancer (OR¼34.3, 95% CI 19.9–59.2). Subjects with bile duct cancer were more likely to
have pigment stones, and with gallbladder cancer to have cholesterol stones (Po0.001). Gallstone weight in gallbladder cancer was
significantly higher than in gallstone patients (4.9 vs 2.8 grams; P¼0.001). We estimate that in Shanghai 80% (95% CI 75–84%), 59%
(56–61%), and 41% (29–59%) of gallbladder, bile duct, and ampulla of Vater cancers, respectively, could be attributed to gallstones.
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Cancers of the biliary tract encompass those arising from the
gallbladder, extrahepatic bile ducts, and ampulla of Vater. Biliary
cancer is relatively uncommon in most parts of the world, although
high-risk populations and upward incidence trends have been
reported in certain areas (Hsing et al, 1998, 2006). Although
gallstones are a well-documented risk factor for gallbladder cancer
(Diehl, 1983, 1991; Zatonski et al, 1997; Lazcano-Ponce et al, 2001;
Hsing et al, 2006), their role in cancers of the extrahepatic bile duct
and ampulla of Vater is less established.
From 1972 to 1994, biliary tract cancer was the most rapidly
rising malignancy in Shanghai (Hsing et al, 1998), involving all
three subsites, both sexes, and all age groups. We therefore
conducted a population-based case–control study there in 1997 to
2001 to assess the role of gallstones for each biliary cancer subsite.
MATERIALS AND METHODS
Cancer cases
The study was approved by the Institutional Review Boards at both
the National Cancer Institute and the Shanghai Cancer Institute.
Informed consent was obtained for all subjects. Patients with
primary biliary tract cancer (ICD9 156), newly diagnosed between
June 1997 and May 2001, were identified through a rapid-reporting
system established between the Shanghai Cancer Institute and 42
collaborating hospitals in 10 urban districts of Shanghai (hence-
forth referred to as urban Shanghai), which captured over 95% of
relevant cases. Cancer cases were permanent residents of urban
Shanghai without a previous non-skin cancer. A total of 627 biliary
cancers were enrolled, representing over 90% of the eligible cases.
Pathology and clinical review
The cancer site was determined from the surgical/pathology report
of the local hospital and confirmed by reviewing radiologic data,
including magnetic resonance imaging, ultrasonography, computer
tomography, and endoscopic retrograde cholangiopancreato-
graphy and histopathology. Because biliary cancer is usually
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ydiagnosed at a fairly late stage, many tumours were unresectable,
and only 458 (68.8%) cases had histological specimens available
for review. Confirmation was both clinical and through indepen-
dent slide review by local pathologists and also by a panel of five
leading Shanghai pathologists and one from the US (AR). A
consensus review was carried out to resolve any discrepancy. Over
74% of gallbladder and 57% of bile duct cancer cases were
confirmed by histology. Whenever possible, staging was evaluated
based on the tumour–node–metastasis system of the American
Joint Committee on Cancer.
For a total of 185 (29%) cases without pathological tissue, mostly
due to unresectable tumours, imaging data as well as clinical and
operative reports were referred to the clinical review panel (four
leading gastrointestinal surgeons and a pathologist). A total of nine
cases with neither tissue nor clinical data for confirmation were
excluded from the study.
Gallstone cases
A total of 1037 patients with biliary stones undergoing cholecys-
tectomy or medical treatment at the same hospital as the index
case were selected and matched by gender and age (within 7 years)
(1) to assess risk factors specific to cancer and (2) to collect such
samples as gallstones, bile, and snap-frozen tissue for biochemical
and molecular analyses. Over 95% of eligible stone cases
participated. Similar clinical and histopathological assessments
of the biliary tract were carried out for all cases with stones.
Population controls
A total of 959 healthy subjects, without a history of cancer, were
randomly selected from the 6.5 million permanent residents of
Shanghai as population controls, using the personal registry cards
of all adults over age 18 in urban Shanghai. They were frequency-
matched to the expected age distribution (5-year category) of the
cancer cases. Controls with a history of non-skin cancer were
ineligible: over 83% of eligible controls participated.
Interviews
In-person interviews were conducted with all study subjects, using
a structured questionnaire, by trained interviewers on potential
risk factors, including smoking, alcohol, body size, diet, repro-
ductive history, family history of cancer, medical history, and
physical activity. Detailed information was obtained on biliary
diseases, including a history of gallstones, date of diagnosis and
treatment, inflammatory conditions, and surgical procedures. Each
interview was taped, reviewed, and verified by a supervisor. In
addition, 5% of the controls were randomly selected for a second
interview within 3 months after the original interview to assess
reproducibility. Concordance between the two interviews was over
95%.
Gallstone status
Great care was taken to ensure the validity of the classification of
gallstone status among study subjects. For cancer cases, in
addition to self-reports of a gallstone history, operative reports
and imaging data were used; details of gallstone location at cancer
diagnosis were collected. Similar procedures were used to confirm
gallstone status in the 1037 gallstone patients. For controls, in
addition to a self-reported gallstone history, transabdominal
ultrasound was performed to validate gallstone status and to
identify silent gallstones. Evidence of biliary sludge based on
ultrasound examination was also recorded, although sludge alone
was not classified as gallstones. One hundred and twenty (13%)
controls did not participate in ultrasound examination; their
gallstone status was determined solely by self-reports.
Biological samples, including overnight fasting blood, gallstones,
and tissue, were collected from study subjects whenever possible.
Information on number, size, colour, and type of gallstones was
obtained from surgical and pathology reports and medical records,
when available; weight was based on the collected stones.
Gallstones were successfully collected from 51 cancer patients
and 520 gallstone patients for morphological and biochemical
classification. Based on the surface and cross-section of the largest
stone, six colour categories were formed: white, light yellow, dark
yellow, light brown, dark brown, and black.
Chemical classification of gallstones
The largest stone was washed by saline and then ground into
powder and analysed for cholesterol, bilirubin, and total and
specific bile acids, such as cholic, chenodeoxycholic, deoxycholic,
glycocholic, glychenodeoxycholic, and glycodeoxycholic acids
(Oda et al, 1975; Roda et al, 1975; Fossati et al, 1989; Wang
et al, 1990). The cholesterol and bile acid content was measured by
high-performance liquid chromatography, while bilirubin concen-
tration was measured by enzymatic methods (Roda et al, 1975;
Han et al, 1998). The collected gallstones were dissolved by adding
10mg of dry gallstone powder in 10ml dimethylsulphoxide, and
were vortexed rigorously for complete dissolving. After addition of
sodium tartrate, the OD value at 600nm was measured on the
Beckman ultraviolet spectrophotometer. Cholesterol concentration
was estimated as: bilirubin (mg per 100mg)¼10 OD (Sample)/
OD (standard reference). Cholesterol stones were defined as stones
whose cholesterol content exceeded 50%.
Statistical analysis
Unconditional logistic regression was used to compute odds ratios
(ORs) and 95% confidence intervals (CIs) for each cancer subsite
associated with gallstones (yes/no) separately, adjusting for age
(o55, 55–64, X65), sex, and educational level (none or primary,
junior middle, senior middle, or some college). Gallbladder cancer
patients were compared with population controls with an intact
gallbladder (without cholecystectomy), while patients with bile
duct or ampullary cancer were compared with control subjects,
since cholecystectomy does not involve the bile duct or ampulla of
Vater. Sex-specific analyses were performed, since gallstones and
gallbladder cancer are more common in women. Covariates,
including cigarette smoking, alcohol use, education, and history of
diabetes or hypertension, were evaluated as potential confounding
variables but excluded from the final regression models since they
did not appreciably change the risk estimates. Joint effects on
biliary cancers of gallstones and several of their risk factors,
including diabetes, body mass index (BMI, weight (kg)/height
(m)
2), chronic cholecystitis, and pancreatitis, were examined by
stratified analysis. A cross-product term was included in the
regression model to evaluate the significance of interactive effects.
All tests were two-sided, with Po0.05 defined as statistically
significant. Attributable risk was calculated using the Epitome
program, using the standard formula PAR¼Pe(RR 1)/
(1þPe(RR 1), where Pe is the prevalence of gallstones among
controls and ORs the estimate of relative risk (RR) (Rothman and
Greenland, 1998).
RESULTS
A total of 627 biliary cancer patients (368 gallbladder, 191 bile
duct, and 68 ampulla of Vater), 1037 stone patients (774
gallbladder and 263 bile duct), and 959 healthy controls were
included. Most cancers were diagnosed at an advanced stage: 70,
61, and 44 of gallbladder, bile duct, and ampulla of Vater cancers,
respectively, were diagnosed at stage III or IV. Of the tumours with
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yhistopathological information, over 90% were adenocarcinomas.
Cancers diagnosed incidentally during surgery for gallstones
accounted for 26.1, 14.1, and 8.8% of the patients with gallbladder,
bile duct, and ampulla of Vater cancers, respectively. Of the 191
extrahepatic bile duct cancers, over half (60%) were in the upper
third (including the cystic duct), 6% in the middle third, 10% in
bile duct not otherwise specified, 18% in the lower third, and 6% in
other or multiple parts. Among gallstone patients, 8.1% had
intestinal metaplasia while 5.3% had dysplasia/carcinoma in situ.
Table 1 shows selected characteristics of cases and controls with
age (due to matching) similar in cancer cases and controls. Those
with biliary stones and no cancer tended to be younger than cancer
cases. Gallbladder cancer was more common in women than men,
while slightly more men had cancers of extrahepatic bile ducts and
ampulla of Vater. Relative to controls, gallbladder cancer patients
had a lower education level, were less likely to smoke or drink
alcohol, more likely to have a history of diabetes, and had a higher
BMI.
Table 2 shows ORs for biliary tract cancer in relation to
gallstones. The overall prevalence of gallstones in the 959 controls
was 23.4%, with 5.9% reporting a history of cholecystectomy,
11.3% of gallstones, and 6.2% having silent gallstones detected
through ultrasound. The 5.5% of controls with biliary sludge or
cholesterol crystals detected on abdominal ultrasound were not
classified as having gallstones. In contrast, a history of gallstones
were found for 83.7, 66.5, and 53% of gallbladder, bile duct, and
ampulla of Vater cancer, respectively. The ORs associated with
stones were 23.8 (95% CI, 17.0–33.4), 8.0 (95% CI 5.6–11.4), and
4.2 (95% CI 2.5–7.0) for cancers of the gallbladder, extrahepatic
bile ducts, and ampulla of Vater, respectively. Further adjustment
for smoking, drinking, BMI, tea drinking, aspirin use, and diabetes
did not materially change the results. Location of gallstones was
recorded for over 73% of the cancer patients with gallstones.
For those with gallbladder cancer, 77% of the stones were in
the gallbladder, 10% in the gallbladder neck, 9% in both the
gallbladder and bile ducts, and 4% in bile ducts alone. The
corresponding percentages for bile duct cancer were 68, 7, 11, and
13%, and for ampullary cancer 57, 0, 14, and 28%. The average age
for biliary tract cancer cases with gallstones was about 5 years
older than that for cases without gallstones (65 vs 60, P¼0.0005).
As shown in Table 3, overall, younger age at gallstone diagnosis
or longer duration of stones alone did not modify the 23-fold risk
associated with gallstones. The very high ORs for bile duct and
ampulla of Vater cancers related to having gallstones for 1 year or
less were due to the frequency of incidental tumours shortly after
or at the time of stone diagnosis. Similar risk patterns were
observed for both men and women (data not shown).
Table 4 shows the combined effects of gallstones and related
factors, including chronic cholecystitis, pancreatitis, diabetes, and
high BMI, on biliary cancer risk. Since gallstones and cholecystitis
may be detected concomitantly with biliary tract cancer, and
gallstones may induce cholecystitis/pancreatitis, subjects with
cholecystitis or pancreatitis diagnosed prior to 2 years of cancer
diagnosis (mostly incidental tumours) or interview were excluded
from the analysis. Subjects with both gallstones and (self-reported)
chronic cholecystitis had a markedly increased risk of biliary
Table 1 Selected characteristics of cases and controls
Biliary tract cancer (n¼267) Biliary stones (n¼1037)
Characteristics Controls
a Controls
b Gallbladder cancer Bile duct cancer Ampulla of Vater cancer Gallbladder stones Bile duct stones
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
959 (100) 902 (100) 368 (100) 191 (100) 68 (100) 774 (100) 263 (100)
Age (years)
o55 128 (13.4) 126 (14.0) 49 (13.3) 30 (15.7) 6 (8.8) 245 (31.6)* 62 (23.6)*
55–64 269 (28.1) 259 (28.7) 96 (26.1) 47 (24.6) 20 (29.4) 218 (28.2) 80 (30.4)
X65 562 (58.6) 517 (57.3) 223 (60.6) 114 (59.7) 42 (61.8) 311 (40.2) 121 (46.0)
Sex
Male 373 (38.9) 357 (39.6) 99 (26.9)* 99 (51.8) 37 (54.4) 263 (34.0)* 127 (48.3)
Female 586 (61.1) 545 (60.4) 269 (73.1) 92 (48.2) 31 (45.6) 511 (66.0) 136 (51.7)
Education
None/primary 396 (41.3) 365 (40.5) 198 (53.8)* 86 (45.0) 29 (42.7) 221 (28.6)* 96 (36.5)
Jr. middle 233 (24.3) 221 (24.5) 79 (21.5) 43 (22.5) 16 (23.5) 220 (28.4) 67 (25.5)
Sr. middle 190 (19.8) 184 (20.4) 50 (13.6) 31 (16.2) 15 (22.1) 194 (25.1) 56 (21.3)
Some college 140 (14.6) 132 (14.6) 41 (11.1) 30 (15.7) 8 (11.8) 139 (18.0) 44 (16.7)
Marital status
Married 751 (78.3) 703 (77.9) 284 (77.2) 161 (84.3) 55 (80.9) 664 (85.8)* 220 (83.7)
Widowed 175 (18.3) 167 (18.5) 77 (20.9) 27 (14.1) 12 (17.7) 96 (12.4) 38 (14.5)
Divorced/separated 21 (2.2) 20 (2.2) 4 (1.1) 1 (0.5) 1 (1.5) 7 (1.0) 2 (0.8)
Never married 12 (1.3) 12 (1.3) 3 (0.8) 2 (1.1) 0 (0.0) 6 (0.8 3 (1.1)
Smoking (%) 285 (29.7) 269 (29.8) 89 (24.2)* 76 (39.8)* 30 (44.1)* 187 (24.2)* 96 (36.5)
Alcohol use (%) 198 (20.7) 186 (20.6) 52 (14.1)* 50 (26.2) 15 (22.1) 116 (15.0)* 51 (19.4)
Diabetes (%) 78 (8.1) 68 (7.5) 51 (13.9)* 20 (10.5) 5 (7.4) 81 (10.5)* 30 (11.4)*
Hypertension (%) 406 (42.3) 376 (41.7) 138 (37.5) 61 (31.9)* 20 (29.4)* 267 (34.5)* 75 (28.5)*
Body mass index
o18.5 79 (8.3) 78 (8.7) 17 (4.7)* 8 (4.2) 1 (1.5) 29 (3.7)* 15 (5.7)*
18.5–22.9 404 (42.2) 390 (43.3) 130 (35.6) 86 (45.5) 29 (42.6) 259 (33.5) 91 (34.7)
23.0–24.9 197 (20.6) 184 (20.4) 73 (20.0) 49 (25.9) 15 (22.1) 197 (25.5) 62 (23.7)
X25.0 278 (29.0) 249 (27.6) 145 (39.7) 46 (24.3) 23 (33.8) 288 (37.3) 94 (35.9)
*w
2 test, Po0.05.
aIncluded all population controls. Bile duct cancer and ampulla of Vater cancer were compared with all population controls.
bExcluded population controls with
a history of cholecystectomy (n¼55) or unknown history (n¼2). Gallbladder cancer cases were compared with this group.
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ycancer, especially of the gallbladder (OR¼34.3; 95% CI 19.9–
59.2), although the interaction between gallstones and the
cholecystitis was not statistically significant. Similarly, subjects
with both gallstones and diabetes had a higher risk of gallbladder
cancer (OR¼30.7, 95% CI 16.7–56.5). BMI and pancreatitis did
not appear to modify the effect, and even among those with a low
BMI (o23kgm
 2); gallstones were a significant risk factor for all
three subsites.
Supplementary Information (see website) shows the morpholo-
gical characteristics of gallstones for 249 biliary cancer patients
(196 gallbladder, 53 bile duct) and 892 stone patients (668
gallbladder, 224 bile duct) as well as the biochemical composition
of gallstones in 530 subjects with stones alone (358 gallbladder, 162
bile duct), 41 with gallbladder cancer, and 10 with bile duct cancer.
Significant differences by subsite were seen in type, number, and
weight, with pigment stones being more common in the bile duct
patients or with bile duct cancer, and cholesterol stones in
gallbladders patients or with gallbladder cancer. Compared with
bile duct cancer, gallbladder cancer patients were more likely to
have multiple (72 vs 58%, P¼0.08), larger, and heavier stones.
Their stones were also heavier (4.9 vs 2.9g, P¼0.006) than those of
gallstone patients, but no significant differences were seen in the
size or number of stones. Patients with bile duct stones or
extrahepatic bile duct cancer had higher levels of bile acids and
bilirubin in their stones than patients with gallbladder stones or
cancer (Po0.001).
DISCUSSION
In this population-based case–control study in Shanghai, we
confirmed that gallstones were a strong risk factor for all three
subsites of biliary cancer. We estimated that 80% (95% CI 0.75–
0.84), 59% (0.50–0.61), and 42% (0.29–0.57) of gallbladder, bile
Table 2 Odds ratios
a and 95% confidence intervals for biliary tract cancer in relation to gallstones, Shanghai, China
Controls
b Controls
c Gallbladder cancer Bile duct cancer Ampulla of Vater cancer
Gallstones n % n % n % OR 95% CI n % OR 95% CI n % OR 95% CI
959 100.0 902 100.0 368 100.0 191 100.0 68 100.0
Total
No 735 76.6 735 81.5 60 16.3 1.0 — 64 33.5 1.0 — 32 47.1 1.0 —
Yes
d 224 23.4 167 18.5 308 83.7 23.8 17.0–33.4 127 66.5 8.0 5.6–11.4 36 53.0 4.2 2.5–7.0
Males
No 313 83.9 313 87.7 24 24.2 1.0 — 40 40.4 1.0 — 20 54.1 1.0 —
Yes
d 60 16.1 44 12.3 75 75.8 23.7 13.3–42.2 59 59.6 8.2 4.9–13.6 17 46.0 4.6 2.3–9.4
Females
No 422 72.0 422 77.4 36 13.4 1.0 — 24 26.1 1.0 — 12 38.7 1.0 —
Yes
d 164 28.0 123 22.6 233 86.6 24.6 16.1–37.7 68 73.9 7.7 4.6–12.9 19 61.3 3.6 1.7–7.6
aAdjusted for age, sex (if applicable), and education level.
bAll population controls. Bile duct cancer and ampulla of Vater cancer were compared with all population controls.
cExcluded population controls with a history of cholecystectomy (n¼55) or unknown history (N¼2). Gallbladder cancer cases were compared with this group.
dIncluded 59
silent gallstones.
Table 3 Odds ratios




Gallbladder cancer Bile duct cancer Ampulla of Vater cancer
nn n OR 95% CI n OR 95% CI n OR 95% CI
Total 959 902 368 191 68
Duration of gallstones (years)
No gallstones 735 735 60 1.0 — 64 1.0 — 32 1.0 —
p1 74 70 138 24.5 16.4–36.5 63 10.2 6.6–15.7 20 6.5 3.5–12.1
2–4 23 17 30 23.6 12.1–45.8 7 3.7 1.5–9.1 2 1.7 0.4–7.7
5–9 47 30 35 14.9 8.5–26.2 11 2.9 1.4–5.9 5 2.4 1.9–6.5
X10 80 50 90 23.3 15.0–36.3 37 5.6 3.5–9.0 4 1.1 1.4–3.2
Age at diagnosis of gallstones
No gallstones 735 735 60 1.0 — 63 1.0 — 32 1.0 —
o45 28 18 41 25.5 13.6–47.8 16 6.2 3.2–12.2 1 0.8 0.1–6.4
45–59 82 53 82 19.2 12.4–29.7 42 6.0 3.8–9.4 9 2.6 1.2–5.6
X60 114 96 173 24.0 16.2–35.6 62 7.2 4.7–11.1 21 4.2 2.3–7.8
Age at diagnosis of gallstones and duration of gallstones
No gallstones 735 735 60 1.0 — 64 1.0 — 32 1.0
o55, p1 year 8 7 12 16.1 5.7–45.3 7 8.8 2.8–27.1 2 8.3 1.4–49.1
o55, 2–5 years 2 2 5 22.1 4.1–120.3 2 9.3 1.3–68.7 1 16.5 1.3–204.3
o55, X6 years 60 38 79 25.6 16.0–38.8 33 6.5 3.9–10.6 4 1.7 0.6–5.1
X55, p1 year 66 63 126 25.4 16.7–38.8 56 10.3 6.6–16.2 18 6.8 3.5–12.9
X55, 2–5 years 34 26 34 17.7 9.7–32.2 8 2.9 1.3–6.7 2 1.5 0.3–6.8
X55, X 6 years 54 31 37 16.8 9.4–30.0 12 2.8 1.4–5.6 4 1.7 0.6–5.2
aAdjusted for age, sex (if applicable), and education level.
bIncluded all population controls. Bile duct cancer and ampulla of Vater cancer were compared with all population
controls.
cExcluded population controls with a history of cholecystectomy (n¼55) or unknown history (N¼2). Gallbladder cancer cases were compared with this group.
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yduct, and ampulla of Vater cancers, respectively, in the Shanghai
population were attributable to gallstones.
Although gallstones are a risk factor common to all three
subsites of biliary cancer, differences in the magnitude of risks and
in the prevalence and type of stones were notable. Molecular
changes, including somatic mutations (such as K-ras and P16) and
loss of heterozygosity, in these subsites have been described
(Rashid et al, 2002; Ueki et al, 2004; Matsuba et al, 2005).
Aetiologic heterogeneity is further supported by ethnic and
geographic patterns between cancer subsites, with gallbladder
cancer incidence especially high in native Americans and in Korea,
India, and Eastern Europe, and the incidence of bile duct cancer
highest in Japan (Hsing et al, 2006).
That cholesterol stones were commoner in gallbladder cancer
while pigment stones predominated in bile duct cancer is
consistent with the view that gallbladder cancer is more associated
with lifestyle factors (diet, obesity, etc.), while bile duct cancer is
associated with chronic infection or inflammation (Cetta, 1991).
Cholesterol stones are associated with lithogenic bile super-
saturated with cholesterol, due to increased hepatic secretion of
cholesterol or diminished secretion of bile salts and phospholipids
that maintain the solubility of cholesterol (el Zayadi et al, 1991). In
contrast, pigment stones have a high biliary concentration and are
closely linked to cirrhosis, chronic infection, and blood disorders
(Swidsinski and Lee, 2001). Cholesterol stones are the commonest
type in western population, while pigment stones predominate
in developing regions of the world, especially in Asia. However, in
China, during the past few decades, there has been an increase in
cholesterol stones and a decrease in pigment stones, probably
related to increasing obesity and a more westernised diet and
lifestyle (Huang and Gu, 1987; Zhu et al, 1995; Wang et al, 2003).
In our study, the magnitude of the biliary cancer risks associated
with gallstones was higher than in most previous studies (Low-
enfels et al, 1985; Vitetta et al, 2000), possibly due to our more
comprehensive assessment of gallstone status. Most previous
studies were smaller (usuallyo100), not population-based, and
lacked subsite-specific risks. A more pronounced association
between gallstones and gallbladder cancer has been reported for
women than men but in our study the effect of gallstone was
similar in both genders.
The carcinogenic mechanisms in biliary cancer are poorly
understood, but they may involve inflammatory changes near
stones (Albores-Saavedra et al, 1980; Carriaga and Henson, 1995).
This is supported by our 34-fold risk associated with gallstones
together with (self-reported) chronic cholecystitis, the possibly
protective effects of aspirin use (Liu et al, 2005), and the
association with a stone pro-inflammatory PTGS gene variant
(Sakoda et al, 2006).
Despite their high risk, only about 1% of gallstone patients
develop biliary cancer (Maringhini et al, 1987), indicating that
other factors are involved. Except for cholecystitis, we did not
detect interactions with other risk factors, perhaps because of
small numbers. Further work is needed to clarify the role of
infection as well as genetic and metabolic factors.
Several strengths of this study are notable. First, selection bias
was minimal due to population-based design with high case
ascertainment and participation. Second, nearly complete con-
firmation of case status minimised misclassification of cases.
Third, the large sample size permitted the investigation of risk
factors by anatomic subsite. Fourth, any misclassification of
gallstones was minimal, since all cases had detailed clinical data,
most controls underwent transabdominal ultrasound examination,
Table 4 Odds ratios
a and 95% confidence intervals for biliary tract cancer in relation to gallstones and other factors, Shanghai, China
Biliary tract cancer
Controls Gallbladder Extrahepatic bile duct Ampulla of Vater
n
b n
c n OR 95% CI n OR 95% CI n OR 95% CI
Gallstones and chronic cholecystitis
d
No gallstones, no cholecystitis 693 693 47 1.0 — 59 1.0 — 27 1.0 —
Chronic cholecystitis only 32 32 4 2.0 0.7–5.8 2 0.9 0.2–3.9 2 1.8 0.4–8.1
Gallstones only 182 136 185 20.9 14.2–30.7 84 6.5 4.4–9.7 31 5.0 2.8–8.7




No gallstones, no pancreatitis 730 730 59 1.0 — 62 1.0 29 1.0 —
Pancreatitis only 4 4 1 3.0 0.3–28.0 1 2.4 0.2–23.3 0 —
Gallstones only 214 163 292 23.2 16.5–32.6 116 7.8 5.4–11.3 33 4.4 2.6–7.5
Gallstones and pancreatitis 10 4 6 20.8 5.6–77.6 7 8.7 3.2–24.2 1 2.5 0.3–20.5
P-interaction 0.37 0.55 0.99
Gallstones and BMI
No gallstones, BMI o23 399 399 31 1.0 — 36 1.0 15 1.0
No gallstones, BMI X23 335 335 28 1.1 0.6–1.8 27 0.9 0.6–1.6 17 1.4 0.7–2.8
Gallstones, BMI o23 77 62 115 25.2 15.4–41.2 57 9.8 5.9–16.4 15 5.7 2.6–12.3
Gallstones, BMI X 23 147 105 191 25.0 15.8–39.3 69 6.6 4.1–10.6 21 4.5 2.2–9.1
P-interaction 0.79 0.36 0.28
Gallstones and diabetes
No gallstones, no diabetes 688 688 55 1.0 — 61 1.0 — 31 1.0 —
Diabetes only 47 47 5 1.5 0.6–4.0 3 0.8 0.3–2.8 1 0.5 0.1–3.8
Gallstones only 193 146 262 23.8 16.7–34.0 110 7.9 5.4–11.5 32 4.2 2.4–7.1
Gallstones and diabetes 31 21 46 30.7 16.7–56.5 17 8.0 4.0–15.9 4 3.3 1.1–10.1
P-interaction 0.79 0.78 0.71
aAdjusted for age, sex, and education level.
bIncluded all population controls. Compared with cancer of the bile duct and ampulla of Vater.
cExcluded population controls with a
history of cholecystectomy (n¼55) or unknown history (N¼2). Compared with cancer of the gallbladder.
dExcluded subjects with cholecystitis or pancreatitis diagnosed within
2 years of cancer diagnosis or interview.
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yand the validity of self-reports of gallstone history was high. Since
only 6% of the population controls had silent gallstones,
misclassification among the 13% of the controls who did not
undergo ultrasound is minimal.
Despite the strong association between gallstones and biliary
cancer, we could not establish a clear temporal relationship due to
our cross-sectional design. However, in previous studies, age at
gallstone diagnosis was usually 10–15 years younger than at
cancer diagnosis, and risks were greatest among those with
gallstones diagnosed at least 10 years earlier (Grimaldi et al, 1993).
Despite this being the largest population-based study of biliary
cancer to date, there was limited statistical power to evaluate the
risk factors for ampulla of Vater cancer and the interactive effect of
stones with other factors for all three subsites.
In summary, this population-based study in Shanghai confirmed
that gallstones are an important risk factor for all three subsites of
biliary cancer, particularly when complicated by chronic cholecystitis.
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